Advertisement

Journal of Clinical Immunology

, Volume 26, Issue 5, pp 430–437 | Cite as

Vasoactive Intestinal Polypeptide Suppressed Experimental Autoimmune Encephalomyelitis by Inhibiting T Helper 1 Responses

  • Haiyan Li
  • Yunhua Mei
  • Ying Wang
  • Lingyun Xu
Article

Abstract

Vasoactive intestinal peptide (VIP) has been found to act as a potent anti-inflammatory factor through regulating the production of both anti- and pro-inflammatory mediators and promoting Th2-type responses. In this study, we used myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (EAE) model in C57BL/6 mice to investigate the potential effects of VIP on multiple sclerosis. Our results showed that in vivo treatment of EAE-induced mice with VIP had great protective benefit at both clinical and histological levels. Disease suppression was associated with the inhibition of T cells proliferation, shifting of the immune response toward a Th2-type response and influencing the expression of pro-inflammatory cytokines including IFN-γ, IL-6 and IL-2 as well as chemotactic factors such as RANTES. In conclusion, the study provides evidence that VIP had great protective effect on EAE through its inhibition actions on pathogenic T cells and through a specific effect on the Th1 response.

KEY WORDS

Vasoactive intestinal polypeptide experimental autoimmune encephalomyelitis T helper 1 cells 

Notes

ACKNOWLEDGMENTS

The helpful advice of Prof. Jingwu Zang was greatly appreciated. This work was supported in part by Science and Technology Commission of Shanghai Municipality (Project 04DZ14902), Shanghai Rising-Star Program (04QMX1423) and Shanghai Leading Academic Discipline Project (T0206).

REFERENCES

  1. 1.
    Said SI, Mutt V: Polypeptide with broad biological activity: Isolation from small intestine. Science 169:1217–1218, 1970.PubMedCrossRefGoogle Scholar
  2. 2.
    Blalock JE: The syntax of immune-neuroendocrine communication. Immunol Today 15:504–511, 1994.PubMedCrossRefGoogle Scholar
  3. 3.
    Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M: Immunology of VIP: A review and therapeutical perspectives. Curr Pharm Des 7:89–111, 2001.PubMedCrossRefGoogle Scholar
  4. 4.
    Pozo D: VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med 9:211–217, 2003.PubMedCrossRefGoogle Scholar
  5. 5.
    Delgado M, Pozo D, Ganea D: The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56:249–290, 2004.PubMedCrossRefGoogle Scholar
  6. 6.
    Calvo JR, Pozo D, Guerrero JM: Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Adv Neuroimmunol 6:39–47, 1996.PubMedCrossRefGoogle Scholar
  7. 7.
    Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA: International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265–270, 1998.PubMedGoogle Scholar
  8. 8.
    Delgado M: VIP: A very important peptide in T helper differentiation. Trends Immunol 24:221–224, 2003.PubMedCrossRefGoogle Scholar
  9. 9.
    Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology 124:961–971, 2003.PubMedCrossRefGoogle Scholar
  10. 10.
    Keino H, Kezuka T, Takeuchi M, Yamakawa N, Hattori T, Usui M: Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol 122:1179–1184, 2004.PubMedCrossRefGoogle Scholar
  11. 11.
    Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7:563–568, 2001.PubMedCrossRefGoogle Scholar
  12. 12.
    Giovannoni G, Hartung HP: The immunopathogenesis of multiple sclerosis and Guillain-Barre syndrome. Curr Opin Neurol 9:165–177, 1996.PubMedCrossRefGoogle Scholar
  13. 13.
    Zamvil SS, Steinman L: The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8:579–621, 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Steinman L: Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24:511–514, 1999.PubMedCrossRefGoogle Scholar
  15. 15.
    Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J: Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis. J Mol Med 75:77–88, 1997.PubMedCrossRefGoogle Scholar
  16. 16.
    Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C: Animal models. Ann Neurol 36(Suppl):S47–S53, 1994.CrossRefGoogle Scholar
  17. 17.
    Teresi S, Boudard F, Bastide M: Effect of calcitonin gene-related peptide and vasoactive intestinal peptide on murine CD4 and CD8 T cell proliferation. Immunol Lett 50:105–113, 1996.PubMedCrossRefGoogle Scholar
  18. 18.
    Delgado M, Chorny A, Gonzalez-Rey E, Ganea D: Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol 78:1327–1338, 2005.PubMedCrossRefGoogle Scholar
  19. 19.
    Ersoy E, Kus CN, Sener U, Coker I, Zorlu Y: The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur J Neurol 12:208–211, 2005.PubMedCrossRefGoogle Scholar
  20. 20.
    Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78–84, 2002.PubMedCrossRefGoogle Scholar
  21. 21.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 96:167–181, 1999.PubMedCrossRefGoogle Scholar
  22. 22.
    Delgado M, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem 274:31930–31940, 1999.PubMedCrossRefGoogle Scholar
  23. 23.
    Delgado M, Leceta J, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol 163:3629–3635, 1999.PubMedGoogle Scholar
  24. 24.
    Ranger AM, Das MP, Kuchroo VK, Glimcher LH: B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int Immunol 8:1549–1560, 1996.PubMedCrossRefGoogle Scholar
  25. 25.
    Ganea D, Delgado M: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 13:229–237, 2002.PubMedCrossRefGoogle Scholar
  26. 26.
    Delgado M, Leceta J, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 16:1844–1846, 2002.PubMedGoogle Scholar
  27. 27.
    Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A: IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 28:2178–2187, 1998.PubMedCrossRefGoogle Scholar
  28. 28.
    Ransohoff RM: The chemokine system in neuroinflammation: An update. J Infect Dis 186(Suppl 2):S152–S156, 2002.PubMedCrossRefGoogle Scholar
  29. 29.
    Delgado M, Ganea D: Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167:966–975, 2001.PubMedGoogle Scholar
  30. 30.
    Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D, Delgado M: Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: Down-regulation of inflammatory and autoimmune responses. Am J Pathol 168:1179–1188, 2006.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Haiyan Li
    • 1
    • 2
  • Yunhua Mei
    • 1
  • Ying Wang
    • 1
  • Lingyun Xu
    • 1
    • 2
    • 3
  1. 1.Shanghai Institute of ImmunologyShanghai Jiao Tong University Medical SchoolShanghaiP. R. China
  2. 2.Institute of Health SciencesShanghai Jiao Tong University/Shanghai Institutes for Biological Sciences, Chinese Academy of SciencesShanghaiP. R. China
  3. 3.Shanghai Institute of ImmunologyShanghai Jiao Tong University Medical SchoolShanghaiP. R. China

Personalised recommendations